# Product Requirement Document (PRD)
## AI-Powered FDA Regulatory Intelligence Platform

---

# 1. Product Overview

## 1.1 Product Name
**AI-Powered FDA Regulatory Intelligence Platform**  
*(Working title: “FDA Copilot for Regulatory Affairs”)*

## 1.2 Product Vision
Build an **AI-native, citation-first regulatory intelligence platform** that enables regulatory professionals to **instantly find, understand, and verify FDA guidance documents with auditable evidence**.

## 1.3 Product Mission
Reduce regulatory research time from **hours/days → seconds/minutes** while maintaining **zero-compromise on accuracy, traceability, and compliance trust**.

---

# 2. Problem Statement

## 2.1 Core Problem

Regulatory Affairs professionals face **inefficient, fragmented, and high-risk workflows** when working with FDA guidance documents.

### Current Reality
- Users spend **30–120 minutes per query**
- Must manually:
  - Search FDA.gov
  - Open multiple PDFs
  - Interpret regulatory language
  - Validate if guidance is draft/final
- No unified system for:
  - Cross-guidance understanding
  - Version tracking
  - Citation validation

---

## 2.2 Key Pain Points

### 1. Inefficient Search & Discovery
- FDA search is **keyword-based only**
- Users must know **exact terminology used by FDA**
- No semantic understanding or contextual retrieval

### 2. Lack of Trustworthy AI Tools
- Generic LLM tools (ChatGPT, etc.) are:
  - Not grounded in FDA corpus
  - Not auditable
  - Risky for compliance use

### 3. No Citation-Level Validation
- Regulatory decisions require:
  - Exact source
  - Section reference
  - Verifiable passage
- Current tools do not provide **audit-ready outputs**

### 4. Version & Change Management Issues
- Draft vs Final guidance confusion
- Silent updates or withdrawals by FDA
- No automated tracking of changes

### 5. High Cost of Expertise
- Regulatory consultants cost:
  - **$300–$700/hour**
- Knowledge is not scalable

---

## 2.3 Business Impact of Problem

- Delayed submissions → **millions in lost revenue**
- Increased risk of:
  - FDA Warning Letters (303 in FY25)
  - Complete Response Letters
- High onboarding time for new regulatory staff
- Loss of institutional knowledge

---

# 3. Product Scope

---

## 3.1 In-Scope (MVP)

### Data Scope
- ✅ FDA Guidance Documents only (~2,788 documents)
- ✅ PDF + metadata ingestion
- ✅ Draft / Final status tracking

---

### Core Features

#### 1. Intelligent Search
- Hybrid search:
  - Keyword (BM25 via OpenSearch)
  - Semantic (vector search via PostgreSQL + pgvector)
- Filters:
  - FDA Center (CDER, CBER, CDRH)
  - Topic
  - Date
  - Status (Draft/Final)

---

#### 2. AI Chat (RAG-based)
- Natural language Q&A over FDA guidance
- Context-aware responses
- Retrieval-grounded answers

---

#### 3. Citation Engine (Critical Feature)
Every response must include:
- Source document
- Section reference
- Exact passage
- Document version
- Confidence score
- Link to FDA source

---

#### 4. Guidance Summarization
- One-click:
  - Summary
  - Key requirements
  - Key changes (draft vs final)

---

#### 5. Document Viewer
- Highlighted passages
- Section navigation
- Inline citations

---

#### 6. Export & Reporting
- Download:
  - Word / PDF summaries
  - Chat transcripts
- Use in:
  - Regulatory submissions
  - Internal reviews

---

#### 7. Update Monitoring
- Daily ingestion of FDA updates
- Alerts for:
  - New guidance
  - Updated guidance
  - Withdrawn guidance

---

## 3.2 Out of Scope (MVP)

- ❌ EMA / PMDA / global regulators
- ❌ FDA Warning Letters / 483 analysis
- ❌ Full RIM workflow (submission management)
- ❌ Agentic automation workflows
- ❌ Fine-tuned proprietary LLM
- ❌ Compliance decision-making (“Am I compliant?”)

---

## 3.3 Future Scope (Post-MVP)

### Phase 2
- Cross-guidance comparison
- Similar guidance discovery
- Draft vs Final diff visualization

### Phase 3
- Warning Letters & 483 integration
- Compliance impact analysis

### Phase 4
- Multi-regulator expansion (EMA, PMDA)
- Regulatory trend analytics

---

# 4. Target Users

## Primary Users

### 1. Regulatory Affairs Specialist
- Needs quick, accurate answers
- High dependency on guidance interpretation

### 2. Regulatory Affairs Director
- Needs audit-ready insights
- Responsible for final submission quality

### 3. Medical Device Compliance Lead
- Needs product-specific guidance discovery
- Works heavily with CDRH documents

### 4. Quality Assurance Manager
- Maps guidance to compliance processes

### 5. Regulatory Consultants
- High-value early adopters
- Need faster billable output

---

# 5. Business Outcomes

---

## 5.1 Primary Outcomes

### 1. Productivity Gains
- ✅ 40–70% reduction in research time
- ✅ Faster decision-making

---

### 2. Risk Reduction
- ✅ Lower probability of:
  - Warning Letters
  - Submission rejections
- ✅ Improved compliance accuracy

---

### 3. Cost Optimization
- ✅ Reduced dependency on consultants
- ✅ Faster onboarding of junior staff

---

### 4. Knowledge Standardization
- ✅ Centralized regulatory intelligence
- ✅ Reduced knowledge silos

---

## 5.2 Quantifiable Metrics

| Metric | Target |
|------|--------|
| Time to answer | < 5 seconds |
| Accuracy (grounded responses) | ≥ 95% |
| Hallucination rate | ≤ 5% |
| Retrieval recall@10 | ≥ 90% |
| User adoption (weekly active) | ≥ 60% |
| NPS (pilot customers) | ≥ 40 |

---

# 6. Value Proposition

## Core Value

> “Ask any FDA regulatory question and get a **verifiable, citation-backed answer in seconds**.”

---

## Differentiators

1. **Citation-first AI (Trust-first design)**
2. **FDA-specific domain intelligence**
3. **Draft vs Final awareness**
4. **Open-source + deploy-anywhere architecture**
5. **Affordable SMB pricing**

---

# 7. High-Level Architecture (MVP)

## Components

### 1. Data Ingestion Layer
- FDA scraper
- PDF parser
- Metadata extractor
- Version tracker

---

### 2. Retrieval Layer
- Vector DB (PostgreSQL + pgvector)
- Keyword search (OpenSearch / BM25)
- Hybrid retrieval
- Re-ranking layer

---

### 3. AI Layer
- LLM (Claude / GPT)
- RAG orchestration
- Prompt templates

---

### 4. Citation Engine
- Passage extraction
- Evidence mapping
- Confidence scoring

---

### 5. Application Layer
- Search UI
- Chat UI
- Document viewer
- Export module

---

# 8. Success Criteria

## MVP Success Definition

The product is successful if:

- Users trust answers **without manual re-validation**
- Regulatory consultants use it **daily**
- First 10 customers are acquired
- Platform demonstrates:
  - High accuracy
  - Low hallucination
  - Strong engagement

---

# 9. Risks & Constraints

## Key Risks

### 1. Trust Failure
- Incorrect citation → product rejection

### 2. Data Freshness Risk
- Outdated guidance → compliance risk

### 3. Competitive Pressure
- Veeva / Cortellis adding AI features

### 4. User Adoption Risk
- Regulatory professionals are risk-averse

---

## Constraints

- Must ensure:
  - High accuracy
  - Explainability
  - Auditability
- Cannot provide:
  - Legal or compliance decisions

---

# 10. Summary

This product addresses a **high-value, high-friction problem** in regulatory workflows by delivering:

- **AI-powered search + reasoning**
- **Citation-backed answers**
- **Regulatory-grade trust**

### Strategic Positioning:
> Not a RIM system  
> Not a generic AI chatbot  
>  
> ✅ A **Regulatory Intelligence Copilot for FDA Guidance**

---

# Final Statement

This PRD defines a **focused, high-impact MVP** that is:
- Technically feasible
- Commercially viable
- Strategically differentiated

The success of this product depends on:
> **Trust > Accuracy > Focus > Speed of execution**